Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gregory

Showing results (441-450 of 512) with videos related to

Pageof 52
Sort By:
ACS Chemical Biology|April 26, 2013
Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complexHeather Sadlish, Gabriela Galicia-Vazquez, C Gregory Paris, et al.
Circulation|April 15, 2009
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patientsGregory Piazza, Erin J Rosenbaum, William Pendergast, et al.
Nature Chemical Biology|April 17, 2024
Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learningRobert I Horne, Ewa A Andrzejewska, Parvez Alam, et al.
Cancer Research Communications|July 17, 2025
In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell CarcinomaRichard C Gregory, Neil Lineberry, Alex Parent, et al.
Pulmonary Circulation|May 18, 2019
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implicationsC Gregory Elliott, Eric D Austin, David Badesch, et al.
Thrombosis and Haemostasis|February 5, 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implicationsGary E Raskob, Alex C Spyropoulos, Julie Zrubek, et al.
American Journal of Human Genetics|October 9, 2001
Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromesK E Heath, A Campos-Barros, A Toren, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 11, 2011
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor modelsThijs H Oude Munnink, Marlous E A Arjaans, Hetty Timmer-Bosscha, et al.
Cell Metabolism|December 3, 2014
γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAORobert A Koeth, Bruce S Levison, Miranda K Culley, et al.
The European Respiratory Journal|April 4, 2015
Validation of two predictive models for survival in pulmonary arterial hypertensionOlivier Sitbon, Raymond L Benza, David B Badesch, et al.
Pageof 52

Showing results (441-450 of 512) with videos related to

Sort By:
Pageof 52
ACS Chemical Biology|April 26, 2013
Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complexHeather Sadlish, Gabriela Galicia-Vazquez, C Gregory Paris, et al.
Circulation|April 15, 2009
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patientsGregory Piazza, Erin J Rosenbaum, William Pendergast, et al.
Nature Chemical Biology|April 17, 2024
Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learningRobert I Horne, Ewa A Andrzejewska, Parvez Alam, et al.
Cancer Research Communications|July 17, 2025
In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell CarcinomaRichard C Gregory, Neil Lineberry, Alex Parent, et al.
Pulmonary Circulation|May 18, 2019
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implicationsC Gregory Elliott, Eric D Austin, David Badesch, et al.
Thrombosis and Haemostasis|February 5, 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implicationsGary E Raskob, Alex C Spyropoulos, Julie Zrubek, et al.
American Journal of Human Genetics|October 9, 2001
Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromesK E Heath, A Campos-Barros, A Toren, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 11, 2011
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor modelsThijs H Oude Munnink, Marlous E A Arjaans, Hetty Timmer-Bosscha, et al.
Cell Metabolism|December 3, 2014
γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAORobert A Koeth, Bruce S Levison, Miranda K Culley, et al.
The European Respiratory Journal|April 4, 2015
Validation of two predictive models for survival in pulmonary arterial hypertensionOlivier Sitbon, Raymond L Benza, David B Badesch, et al.
Pageof 52